Lisa Van den Bosch1, Hans Paul van der Laan2, Arjen van der Schaaf2, Sjoukje F Oosting3, Gyorgy B Halmos4, Max J H Witjes5, Edwin Oldehinkel2, Tineke W H Meijer2, Johanna G M van den Hoek2, Roel J H M Steenbakkers2, Johannes A Langendijk2. 1. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: l.g.l.j.van.den.bosch@umcg.nl. 2. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
PURPOSE: Radiation therapy is an effective but burdensome treatment for head and neck cancer (HNC). We aimed to characterize the severity and time pattern of patient-reported symptoms and quality of life in a large cohort of patients with HNC treated with definitive radiation therapy, with or without systemic treatment. METHODS AND MATERIALS: A total of 859 patients with HNC treated between 2007 and 2017 prospectively completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Head and Neck Cancer module (QLQ-HN35) and Core Quality of Life Questionnaire (QLQ-C30) at regular intervals during and after treatment for up to 5 years. Patients were classified into 3 subgroups: early larynx cancer, infrahyoideal cancer, and suprahyoideal cancer. Outcome scales of both questionnaires were quantified per subgroup and time point by means of average scores and the frequency distribution of categorized severity (none, mild, moderate, and severe). Time patterns and symptom severity were characterized. Toxicity profiles were compared using linear mixed model analysis. Additional toxicity profiles based on age, human papillomavirus status, treatment modality, smoking status, tumor site, and treatment period were characterized as well. RESULTS: The study population consisted of 157 patients with early larynx cancer, 304 with infrahyoideal cancer, and 398 with suprahyoideal cancer. The overall questionnaire response rate was 83%. Generally, the EORTC QLQ-HN35 symptoms reported showed a clear time pattern, with increasing scores during treatment followed by a gradual recovery in the first 2 years. Distinct toxicity profiles were seen across subgroups (P < .001), with generally less severe symptom scores in the early larynx subgroup. The EORTC QLQ-C30 functioning, quality-of-life, and general symptoms reported showed a less evident time pattern and less pronounced differences in mean scores between subgroups, although differences were still significant (P < .001). Differences in mean scores were most pronounced for role functioning, appetite loss, fatigue, and pain. CONCLUSIONS: We established patient-reported toxicity and quality-of-life profiles that showed different patterns for 3 subgroups of patients with HNC. These profiles provide detailed information on the severity and persistence of various symptoms as experienced by patients during and after definitive radiation therapy. These profiles can be used to inform treatment of future patients and may serve as a benchmark for future studies.
PURPOSE: Radiation therapy is an effective but burdensome treatment for head and neck cancer (HNC). We aimed to characterize the severity and time pattern of patient-reported symptoms and quality of life in a large cohort of patients with HNC treated with definitive radiation therapy, with or without systemic treatment. METHODS AND MATERIALS: A total of 859 patients with HNC treated between 2007 and 2017 prospectively completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Head and Neck Cancer module (QLQ-HN35) and Core Quality of Life Questionnaire (QLQ-C30) at regular intervals during and after treatment for up to 5 years. Patients were classified into 3 subgroups: early larynx cancer, infrahyoideal cancer, and suprahyoideal cancer. Outcome scales of both questionnaires were quantified per subgroup and time point by means of average scores and the frequency distribution of categorized severity (none, mild, moderate, and severe). Time patterns and symptom severity were characterized. Toxicity profiles were compared using linear mixed model analysis. Additional toxicity profiles based on age, human papillomavirus status, treatment modality, smoking status, tumor site, and treatment period were characterized as well. RESULTS: The study population consisted of 157 patients with early larynx cancer, 304 with infrahyoideal cancer, and 398 with suprahyoideal cancer. The overall questionnaire response rate was 83%. Generally, the EORTC QLQ-HN35 symptoms reported showed a clear time pattern, with increasing scores during treatment followed by a gradual recovery in the first 2 years. Distinct toxicity profiles were seen across subgroups (P < .001), with generally less severe symptom scores in the early larynx subgroup. The EORTC QLQ-C30 functioning, quality-of-life, and general symptoms reported showed a less evident time pattern and less pronounced differences in mean scores between subgroups, although differences were still significant (P < .001). Differences in mean scores were most pronounced for role functioning, appetite loss, fatigue, and pain. CONCLUSIONS: We established patient-reported toxicity and quality-of-life profiles that showed different patterns for 3 subgroups of patients with HNC. These profiles provide detailed information on the severity and persistence of various symptoms as experienced by patients during and after definitive radiation therapy. These profiles can be used to inform treatment of future patients and may serve as a benchmark for future studies.
Authors: Gerda M Verduijn; Marta E Capala; Nienke D Sijtsema; Iris Lauwers; Juan A Hernandez Tamames; Wilma D Heemsbergen; Aniel Sewnaik; Jose A Hardillo; Hetty Mast; Yvette van Norden; Maurice P H M Jansen; Aad van der Lugt; Dik C van Gent; Mischa S Hoogeman; Bianca Mostert; Steven F Petit Journal: BMJ Open Date: 2022-05-18 Impact factor: 3.006
Authors: Vicente Escudero-Vilaplana; Lorena Romero-Medrano; Cristina Villanueva-Bueno; Marta Rodríguez de Diago; Alberto Yánez-Montesdeoca; Roberto Collado-Borrell; Juan José Campaña-Montes; Belén Marzal-Alfaro; José Luis Revuelta-Herrero; Antonio Calles; Mar Galera; Rosa Álvarez; Ana Herranz; María Sanjurjo; Antonio Artés-Rodríguez Journal: Front Oncol Date: 2022-07-13 Impact factor: 5.738
Authors: Aniek T Zwart; Wolf Pörtzgen; Irene van Rijn-Dekker; Grigory A Sidorenkov; Rudi A J O Dierckx; Roel J H M Steenbakkers; Inge Wegner; Anouk van der Hoorn; Geertruida H de Bock; Gyorgy B Halmos Journal: J Clin Med Date: 2022-08-09 Impact factor: 4.964
Authors: Rosanne C Schoonbeek; Julius de Vries; Linda Bras; Grigory Sidorenkov; Boudewijn E C Plaat; Max J H Witjes; Bernard F A M van der Laan; Johanna G M van den Hoek; Boukje A C van Dijk; Johannes A Langendijk; György B Halmos Journal: Eur J Cancer Care (Engl) Date: 2022-04-19 Impact factor: 2.328
Authors: Amy L Shaver; Katia Noyes; Heather M Ochs-Balcom; Gregory Wilding; Andrew D Ray; Sung Jun Ma; Mark Farrugia; Anurag K Singh; Mary E Platek Journal: Cancers (Basel) Date: 2021-08-25 Impact factor: 6.639